Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors

Authors
Category Primary study
JournalMolecular Cancer Therapeutics
Year 2011
This article has no abstract
Epistemonikos ID: a321662b401ade2c7267155317714c41ee710994
First added on: Feb 04, 2025